JP2025510826A5 - - Google Patents

Info

Publication number
JP2025510826A5
JP2025510826A5 JP2024556658A JP2024556658A JP2025510826A5 JP 2025510826 A5 JP2025510826 A5 JP 2025510826A5 JP 2024556658 A JP2024556658 A JP 2024556658A JP 2024556658 A JP2024556658 A JP 2024556658A JP 2025510826 A5 JP2025510826 A5 JP 2025510826A5
Authority
JP
Japan
Prior art keywords
solid form
solid
further characterized
xrpd
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510826A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/064916 external-priority patent/WO2023183910A1/en
Publication of JP2025510826A publication Critical patent/JP2025510826A/ja
Publication of JP2025510826A5 publication Critical patent/JP2025510826A5/ja
Pending legal-status Critical Current

Links

JP2024556658A 2022-03-25 2023-03-24 Ｔｙｋ２阻害剤の固体形態及び使用方法 Pending JP2025510826A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263269944P 2022-03-25 2022-03-25
US63/269,944 2022-03-25
PCT/US2023/064916 WO2023183910A1 (en) 2022-03-25 2023-03-24 Solid forms of tyk2 inhibitors and methods of use

Publications (2)

Publication Number Publication Date
JP2025510826A JP2025510826A (ja) 2025-04-15
JP2025510826A5 true JP2025510826A5 (cg-RX-API-DMAC7.html) 2026-03-31

Family

ID=88102056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556658A Pending JP2025510826A (ja) 2022-03-25 2023-03-24 Ｔｙｋ２阻害剤の固体形態及び使用方法

Country Status (5)

Country Link
US (1) US20250215002A1 (cg-RX-API-DMAC7.html)
EP (1) EP4499645A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025510826A (cg-RX-API-DMAC7.html)
CN (1) CN118974052A (cg-RX-API-DMAC7.html)
WO (1) WO2023183910A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025107861A1 (zh) * 2023-11-24 2025-05-30 苏州科睿思制药有限公司 Zasocitinib的晶型及其制备方法和用途
WO2025191534A1 (en) 2024-03-14 2025-09-18 Assia Chemical Industries Ltd. Solid state forms of zasocitinib and process for preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202515876A (zh) * 2017-03-08 2025-04-16 日商武田藥品工業股份有限公司 Tyk2抑制劑及其用途
SI3658557T1 (sl) * 2017-07-28 2024-10-30 Takeda Pharmaceutical Company Limited Zaviralci TYK2 in njihova uporaba
GB202005114D0 (en) * 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound

Similar Documents

Publication Publication Date Title
JP2025510826A5 (cg-RX-API-DMAC7.html)
JP2023519891A5 (cg-RX-API-DMAC7.html)
JP2020512316A5 (cg-RX-API-DMAC7.html)
AU593295B2 (en) Paroxetine hydrochloride hemihydrate
JP2004534803A5 (cg-RX-API-DMAC7.html)
WO2003037881A1 (en) α-FORM OR ß-FORM CRYSTAL OF ACETANILIDE DERIVATIVE
JP2020511461A5 (cg-RX-API-DMAC7.html)
WO2008059029A2 (en) New polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate
JP2019504103A5 (cg-RX-API-DMAC7.html)
JP2022511800A5 (cg-RX-API-DMAC7.html)
US8158607B2 (en) Crystalline form of lamivudine
JP2013538849A5 (cg-RX-API-DMAC7.html)
JP2010535742A5 (cg-RX-API-DMAC7.html)
JP2009521414A5 (cg-RX-API-DMAC7.html)
JP2024095561A5 (cg-RX-API-DMAC7.html)
JP2022553833A5 (cg-RX-API-DMAC7.html)
JP2020073513A (ja) α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
CN107698574B (zh) 一种高纯度阿瑞匹坦的精制制备工艺
CA2824301A1 (en) F, g, h, i and k crystal forms of imatinib mesylate
RU2007132701A (ru) Полиморфная модификация а ибандроната
JP2022540678A5 (cg-RX-API-DMAC7.html)
JP2018030884A (ja) テノホビルの固体形態
JP2015531354A5 (cg-RX-API-DMAC7.html)
JP2025509988A5 (cg-RX-API-DMAC7.html)
RU2007143025A (ru) Полиморфизм додекагидроклопента[а]фенантренилового эфира тиофенкарбоновой кислоты